2024
Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant‐level pooled analysis of DAPA‐HF and DELIVER
Peikert A, Vaduganathan M, Claggett B, Kulac I, Foà A, Desai A, Jhund P, Carberry J, Lam C, Kosiborod M, Inzucchi S, Martinez F, de Boer R, Hernandez A, Shah S, Køber L, Ponikowski P, Sabatine M, Petersson M, Langkilde A, McMurray J, Solomon S. Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant‐level pooled analysis of DAPA‐HF and DELIVER. European Journal Of Heart Failure 2024, 26: 912-924. PMID: 38487939, DOI: 10.1002/ejhf.3184.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionHeart failureHistory of MIMyocardial infarctionPrimary outcomeDAPA-HFWorsening HFSpectrum of left ventricular ejection fractionLeft ventricular ejection fraction spectrumCardiovascular deathSodium-glucose cotransporter 2 inhibitorsRisk of disease progressionComposite of cardiovascular deathRisk of adverse cardiovascular outcomesIncreased risk of adverse cardiovascular outcomesRisk of cardiovascular deathVentricular ejection fractionHistory of myocardial infarctionSerious adverse eventsAdverse cardiovascular outcomesSymptomatic HFEjection fractionAdverse eventsCovariate-adjusted modelsPooled analysis
2023
Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease
Tan X, Liang Y, Rajpura J, Yedigarova L, Noone J, Xie L, Inzucchi S, de Havenon A. Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease. Cardiovascular Diabetology 2023, 22: 319. PMID: 37985992, PMCID: PMC10662529, DOI: 10.1186/s12933-023-02051-8.Peer-Reviewed Original ResearchConceptsHealth care resource utilizationAtherosclerotic cardiovascular diseaseGLP-1 RAsCause health care resource utilizationPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsDPP-4i usersPeptidase-4 inhibitorsMyocardial infarctionMedical costsDPP-4iIschemic strokeReceptor agonistCardiovascular diseaseGlucagon-like peptide-1 receptor agonistsWeekly glucagon-like peptide-1 receptor agonistWeekly GLP-1 RAsCause ER visitsCause hospitalization costsCause medical costsNew adult usersClinical cardiovascular outcomesObservational cohort studyType 2 diabetesCause outpatient visits